| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Surgical Oncology, 2 Division of Quantitative Sciences and 3 Department of Gastrointestinal Medical Oncology, Anderson Cancer Center, The University of Texas M.D., Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, Texas 77030, USA
(Correspondence should be addressed to F Meric-Bernstam; Email: fmeric{at}mdanderson.org)
The mammalian target of rapamycin (mTOR) signaling pathway has emerged as a promising target for cancer therapy. Rapamycin inhibits mTOR activity but induces upstream signaling, leading to Akt activation, potentially limiting antitumor activity. Octreotide, a somatostatin analog, decreases phosphatidylinositol-3-kinase/Akt signaling in some models, and thus theoretically may enhance rapamycin's antitumor activity. The aim of this study was to determine the antitumor activity of rapamycin and octreotide as single agents and in combination in neuroendocrine tumors. In carcinoid cell lines BON-1 and NCI-H727, cell proliferation was significantly inhibited by rapamycin in vitro, although rapamycin treatment did lead to Akt phosphorylation. Octreotide had limited antiproliferative effects alone, and did not demonstrate synergistic or additive interactions with rapamycin. Furthermore, octreotide did not overcome rapamycin-induced Akt phosphorylation. In vivo, rapamycin alone caused significant tumor suppression. Octreotide alone did not inhibit in vivo tumor growth and did not enhance rapamycin-mediated growth inhibition. In conclusion, rapamycin causes significant growth inhibition in carcinoid tumor cell lines in vitro and in vivo, thus mTOR is a promising therapeutic target for neuroendocrine tumors. Octreotide does not enhance the efficacy of rapamycin's antiproliferative effects in the models tested, and does not inhibit rapamycin-mediated feedback activation of Akt. Further study is needed in order to determine whether octreotide or other somatostatin analogs enhance the efficacy of mTOR inhibitors in other models.
This article has been cited by other articles:
|
|
 |
|
  V. Cerovac, J. Monteserin-Garcia, H. Rubinfeld, M. Buchfelder, M. Losa, T. Florio, M. Paez-Pereda, G. K. Stalla, and M. Theodoropoulou The Somatostatin Analogue Octreotide Confers Sensitivity to Rapamycin Treatment on Pituitary Tumor Cells Cancer Res., January 15, 2010; 70(2): 666 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Yao, C. Lombard-Bohas, E. Baudin, L. K. Kvols, P. Rougier, P. Ruszniewski, S. Hoosen, J. St. Peter, T. Haas, D. Lebwohl, et al. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial J. Clin. Oncol., January 1, 2010; 28(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Dahan, F. Bonnetain, P. Rougier, J.-L. Raoul, E. Gamelin, P.-L. Etienne, G. Cadiot, E. Mitry, D. Smith, F. Cvitkovic, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon {alpha} for advanced carcinoid tumors: FNCLCC-FFCD 9710 Endocr. Relat. Cancer, December 1, 2009; 16(4): 1351 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Meric-Bernstam and A. M. Gonzalez-Angulo Targeting the mTOR Signaling Network for Cancer Therapy J. Clin. Oncol., May 1, 2009; 27(13): 2278 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Yao, A. T. Phan, D. Z. Chang, R. A. Wolff, K. Hess, S. Gupta, C. Jacobs, J. E. Mares, A. N. Landgraf, A. Rashid, et al. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study J. Clin. Oncol., September 10, 2008; 26(26): 4311 - 4318. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
